Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells

The most commonly used drug in the treatment of women with hormone-dependent breast cancer is tamoxifen. A recent study addressed the issue of tamoxifen leading to a resistance against the drug by investigating the underlying mechanisms, utilizing a GPR30 antibody that is available at antibodies-online.
Continuous treatment of MCF-7 cells (breast cancer cell line) for six months led to resistance against tamoxifen. Similarly, continuous treatment with an agonist for the new estrogen G-protein coupled receptor increases tamoxifen resistance. Hence, this data suggests that receptor signaling is involved in the mediation of tamoxifen induced resistance against this anti-cancer drug. offers a range of .